# Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery

> **NCT07746349** · NA · NOT_YET_RECRUITING · sponsor: **Sevil Cankaya** · enrollment: 80 (estimated)

## Conditions studied

- Uterine Fibroids (Leiomyoma)
- Uterine Myoma
- Leiomyoma

## Interventions

- **DRUG:** terlipressin (vasoconstrictor)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07746349
- **Lead sponsor:** Sevil Cankaya
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746349, "Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*